<DOC>
	<DOCNO>NCT00232505</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give cetuximab together carboplatin effective give cetuximab alone treat metastatic breast cancer . PURPOSE : This randomized phase II trial study cetuximab carboplatin see well work compare cetuximab alone treat woman estrogen receptor-negative ( ER- ) , progesterone receptor-negative ( PR- ) metastatic breast cancer .</brief_summary>
	<brief_title>Cetuximab + / - Carboplatin Estrogen Receptor-Negative , Progesterone Receptor-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall response rate woman estrogen receptor-negative , progesterone receptor-negative , HER2-nonoverexpressing metastatic breast cancer treat cetuximab v without carboplatin . Secondary - Compare time disease progression patient treat regimen . - Correlate downstream effect EGFR inhibitor MAPK , AKT , Ki67 , EGFR-dependent signaling , proliferation , apoptosis toxicity response patient accessible tumor treat regimen . - Determine change biomarkers gene expression circulate tumor cell treatment . - Compare overall survival rate patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cetuximab IV 60-120 minute week . - Arm II : Patients receive cetuximab arm I carboplatin IV day 1 , 8 , 15 . In arm , treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients respond treatment arm I may cross arm II . Blood sample collect periodically throughout study correlative biomarker analysis IHC gene expression analysis . After completion study treatment , patient follow every 4 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Metastatic ( stage IV ) disease Measurable disease RECIST criterion Irradiated lesion consider measurable disease CNS metastases allow disease stable ( evidence progression ) ≥ 3 month local therapy No lesion identifiable PET scan HER2 nonoverexpressing disease IHC ( 0 1 ) nongene amplify FISH HER2 2+ IHC allow Hormone receptor status : Estrogen receptornegative progesterone receptornegative tumor PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 6 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine clearance ≥ 50 mL/min ALT AST ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN case liver metastasis ) Bilirubin ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant history uncontrolled cardiac disease include , limited , follow : Uncontrolled hypertension Unstable angina Recent myocardial infarction ( within past 6 month ) Uncontrolled congestive heart failure Cardiomyopathy either symptomatic asymptomatic decrease ejection fraction &lt; 45 % No history severe infusion reaction monoclonal antibody treatment No uncontrolled infection No major medical condition ( i.e. , uncontrolled pulmonary , renal , hepatic dysfunction ) may affect study participation No significant comorbid condition may compromise effective safe participation study PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior chemotherapy At least 2 week since prior radiation therapy No 3 prior chemotherapy regimens either adjuvant metastatic set Sequential regimen ( e.g. , anthracyclinepaclitaxel ) consider 1 regimen No prior therapy specifically directly target EGFR pathway therapeutic intent No prior platinum agent metastatic disease Prior platinum agent adjuvant setting allow provide diseasefree interval last ≥ 12 month prior relapse Concurrent bisphosphonates allow Bone lesion may use measure progression response</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>